Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 6 | 2020 | 759 | 2.540 |
Why?
|
| Heart Failure | 10 | 2020 | 1719 | 2.480 |
Why?
|
| Heart-Assist Devices | 3 | 2019 | 387 | 1.560 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 230 | 1.440 |
Why?
|
| Cardiology | 2 | 2020 | 282 | 1.310 |
Why?
|
| Patient Selection | 2 | 2020 | 693 | 1.290 |
Why?
|
| Registries | 4 | 2019 | 1661 | 1.010 |
Why?
|
| Waiting Lists | 2 | 2019 | 106 | 0.980 |
Why?
|
| Population Health | 1 | 2020 | 27 | 0.880 |
Why?
|
| BK Virus | 1 | 2019 | 20 | 0.870 |
Why?
|
| Patient Advocacy | 1 | 2019 | 66 | 0.830 |
Why?
|
| Viremia | 1 | 2019 | 111 | 0.820 |
Why?
|
| Stroke Volume | 2 | 2020 | 462 | 0.810 |
Why?
|
| Immunocompromised Host | 2 | 2020 | 220 | 0.790 |
Why?
|
| Rosa | 1 | 2018 | 2 | 0.790 |
Why?
|
| Renal Insufficiency | 1 | 2019 | 110 | 0.790 |
Why?
|
| Triage | 1 | 2020 | 177 | 0.770 |
Why?
|
| Organizational Objectives | 1 | 2017 | 70 | 0.720 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 68 | 0.720 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2018 | 88 | 0.710 |
Why?
|
| Health Policy | 1 | 2020 | 336 | 0.710 |
Why?
|
| Mentoring | 1 | 2017 | 49 | 0.700 |
Why?
|
| Pacemaker, Artificial | 1 | 2018 | 108 | 0.700 |
Why?
|
| Cardiovascular System | 1 | 2017 | 106 | 0.690 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 605 | 0.680 |
Why?
|
| Heart Diseases | 1 | 2020 | 375 | 0.670 |
Why?
|
| Betacoronavirus | 1 | 2020 | 273 | 0.670 |
Why?
|
| Mentors | 1 | 2017 | 124 | 0.650 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 385 | 0.630 |
Why?
|
| Translational Medical Research | 1 | 2017 | 199 | 0.590 |
Why?
|
| Health Services Research | 1 | 2017 | 400 | 0.580 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 357 | 0.570 |
Why?
|
| Quality Improvement | 2 | 2020 | 803 | 0.560 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 374 | 0.560 |
Why?
|
| Biomedical Research | 1 | 2017 | 574 | 0.480 |
Why?
|
| Medication Adherence | 1 | 2016 | 506 | 0.460 |
Why?
|
| Defibrillators, Implantable | 1 | 2014 | 351 | 0.440 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2019 | 100 | 0.370 |
Why?
|
| United States | 6 | 2019 | 11035 | 0.320 |
Why?
|
| Humans | 17 | 2020 | 104249 | 0.310 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 1117 | 0.240 |
Why?
|
| Pericarditis | 1 | 2020 | 15 | 0.230 |
Why?
|
| Cryptococcus neoformans | 1 | 2020 | 21 | 0.220 |
Why?
|
| Cryptococcosis | 1 | 2020 | 30 | 0.220 |
Why?
|
| Cardiologists | 1 | 2020 | 37 | 0.220 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 2653 | 0.220 |
Why?
|
| Female | 10 | 2020 | 59707 | 0.210 |
Why?
|
| Treatment Outcome | 4 | 2020 | 8608 | 0.210 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 4685 | 0.200 |
Why?
|
| Adult | 7 | 2020 | 30359 | 0.200 |
Why?
|
| Risk Assessment | 2 | 2020 | 2934 | 0.200 |
Why?
|
| Cardiotonic Agents | 1 | 2019 | 137 | 0.190 |
Why?
|
| Long-Term Care | 1 | 2018 | 71 | 0.190 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 67 | 0.190 |
Why?
|
| Viral Load | 1 | 2019 | 419 | 0.180 |
Why?
|
| Male | 9 | 2020 | 58392 | 0.180 |
Why?
|
| Community Health Services | 1 | 2019 | 203 | 0.180 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 408 | 0.180 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2017 | 42 | 0.180 |
Why?
|
| Cohort Studies | 2 | 2018 | 4560 | 0.180 |
Why?
|
| Patient Participation | 1 | 2020 | 343 | 0.180 |
Why?
|
| Stakeholder Participation | 1 | 2017 | 51 | 0.170 |
Why?
|
| Professional Competence | 1 | 2017 | 109 | 0.170 |
Why?
|
| Patient Safety | 1 | 2020 | 311 | 0.170 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2016 | 9 | 0.170 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 192 | 0.160 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2016 | 55 | 0.160 |
Why?
|
| Career Choice | 1 | 2017 | 181 | 0.160 |
Why?
|
| Interprofessional Relations | 1 | 2017 | 267 | 0.150 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1433 | 0.150 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 6518 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 515 | 0.150 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 215 | 0.150 |
Why?
|
| Dyspnea | 1 | 2015 | 168 | 0.150 |
Why?
|
| Medicare | 1 | 2018 | 472 | 0.150 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2014 | 50 | 0.140 |
Why?
|
| Pandemics | 1 | 2020 | 585 | 0.140 |
Why?
|
| Postoperative Care | 1 | 2016 | 285 | 0.140 |
Why?
|
| Antiviral Agents | 1 | 2019 | 601 | 0.140 |
Why?
|
| Health Care Costs | 1 | 2017 | 392 | 0.140 |
Why?
|
| Medicaid | 1 | 2017 | 354 | 0.140 |
Why?
|
| Aged | 5 | 2020 | 18934 | 0.140 |
Why?
|
| Survival Rate | 1 | 2018 | 1755 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 922 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1206 | 0.130 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 436 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2016 | 1406 | 0.120 |
Why?
|
| Retrospective Studies | 2 | 2018 | 10064 | 0.120 |
Why?
|
| Curriculum | 1 | 2017 | 744 | 0.120 |
Why?
|
| European Continental Ancestry Group | 1 | 2017 | 1337 | 0.120 |
Why?
|
| African Americans | 1 | 2017 | 1040 | 0.110 |
Why?
|
| Logistic Models | 1 | 2016 | 1984 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1587 | 0.110 |
Why?
|
| Hispanic Americans | 1 | 2017 | 1051 | 0.110 |
Why?
|
| Age Factors | 1 | 2018 | 3221 | 0.110 |
Why?
|
| Postoperative Complications | 1 | 2019 | 2086 | 0.100 |
Why?
|
| Time Factors | 2 | 2016 | 7066 | 0.090 |
Why?
|
| Risk Factors | 1 | 2020 | 8467 | 0.090 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 4151 | 0.080 |
Why?
|
| Hospitalization | 1 | 2014 | 1486 | 0.080 |
Why?
|
| Middle Aged | 4 | 2020 | 27633 | 0.070 |
Why?
|
| Pericardiocentesis | 1 | 2020 | 13 | 0.060 |
Why?
|
| Fluconazole | 1 | 2020 | 14 | 0.060 |
Why?
|
| Health Services Misuse | 1 | 2020 | 38 | 0.060 |
Why?
|
| Antifungal Agents | 1 | 2020 | 144 | 0.050 |
Why?
|
| Organ Transplantation | 1 | 2020 | 153 | 0.050 |
Why?
|
| Echocardiography | 1 | 2020 | 614 | 0.040 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 374 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2017 | 132 | 0.040 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2015 | 88 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 1040 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 521 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2017 | 194 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2017 | 249 | 0.040 |
Why?
|
| Linear Models | 1 | 2017 | 876 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2015 | 677 | 0.030 |
Why?
|
| Acute Disease | 1 | 2015 | 978 | 0.030 |
Why?
|
| Exercise Test | 1 | 2015 | 578 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2015 | 689 | 0.030 |
Why?
|
| Prognosis | 1 | 2015 | 3289 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 3163 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2015 | 5605 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 10261 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 17541 | 0.010 |
Why?
|